Sorry AIDS, your day in the sun is over. We've got you beat now. If not fully cured, we have the ability to completely halt the progress, and with drugs that are now available as low cost generics. But Hep-C, you're a real animal there, and right now, only Gilead Science (GILD) and their flagship brand Harvoni is getting the job done. Harvoni sees cure rates (Fully cured, no need to ever use it again) in 94-99% of the patients who use it. If you're bad enough off, you can get your insurance company to fork over up to $90,000 to get it done. It's a small price to pay to never have to be in the hospital again. And for investors, the nice 2.02% dividend yield will keep us happy until they have the cure for whatever the next awful disease is. Gilead closed down 44 cents today to $87.36. I am long the shares.